drugset / Trial / NCT00943943
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
Phase 1
Completed
33 enrolled
M.D. Anderson Cancer Center
Amgen · collabBayer · collabGenzyme, a Sanofi Company · collabGeorgia Institute of Technology · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn the most tolerable dose of Nexavarâ (sorafenib) when given in combination with Mobozilâ (plerixafor) and Neupogenâ (filgrastim) to patients with AML. The safety of this combination will also be studied. Funding Source - FDA OOPD
Timeline
- Start
- 2010-10-29
- Primary completion
- 2017-03-23
- Completion
- 2017-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Background | G-CSF | Unknown | 10 ug/kg | Subcutaneous |
| Background | Plerixafor | Small molecule | 240 ug/kg | Subcutaneous |